

**△ Lindsley F. Kimball Research Institute**

A Division of the New York Blood Center

Placental Blood Program

310 E. 67th Street, New York, NY 10021

212/570-3230 Fax 212/570-3393

7212 '01 MAY -9 P1:16

May 8, 2001

Dockets Management Branch  
Food and Drug Administration  
5630 Fishers Lane, rm 1061  
Rockville, MD 20852

Ref. Docket No. 97N-484P: Current Good Tissue Practice for Manufacturers of Human Cellular and Tissue-based Products: Inspection and Enforcement.

Gentlemen:

I write as the Director of the Placental Blood Program of the New York Blood Center. This Program was initially established in 1992, with funding from NHLBI, to test the feasibility of using Placental/Umbilical Cord blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. The Program developed standards for the collection, processing, testing, cryoprotection, freezing and storing cord blood units for eventual selection by bone marrow transplant physicians in recognized Transplant Centers. Since 1996 the Program has worked under an IND exception from FDA (BB IND 6637). During its life, the Program has collected close to 14,000 cord blood specimens and issued over 1100 cord blood units to patients in over 140 transplant centers worldwide. Over 1070 of these have been already transplanted.

During this time numerous other groups in the US, Europe, Japan and elsewhere have started similar Programs. Many of them are directed by reputable individuals and are under at least some regulatory supervision, their respective Standards are different. A number of these Banks have also provided excellent grafts to patients in the US and others may do so in the near future. Not all Banks, however, have provided equally acceptable transplants and patients may have suffered as a consequence. Recent efforts from FAHCT and NETCORD to provide an international set of Standards for cord blood banking notwithstanding, the definition of thorough rules for Good Tissue Practice by the US FDA adds, in my opinion, a necessary ingredient to the protection of transplant recipients.

The rules contained in proposed new Part 1271 (title 21 CFR) represent an exhaustive effort to identify all or most of the elements that can be used to document compliance with current Good Tissue Practices. I believe the proposed rules are reasonable and will help assure the safety of use of such grafts for

97N-484P

C 37

transplant recipients. Clearly, our Program will need to implement more rigorous documentation procedures and will make the necessary personnel investment.

I do have a minor suggestion with respect to subpart 350, which deals with Reporting. The proposed rule indicates the responsibility to report by "Any establishment that receives information about an adverse reaction." In fact, given the need to investigate all cases in which an adverse event may conceivably be due to a noxious effect of the graft, it might be important to specify the need to facilitate, encourage and even solicit this information by the cord blood Banks themselves. In fact, the probability of receiving such information in some cases may be determined in part by the presence of absence of a well-defined active follow-up program implemented by the Bank.

Respectfully submitted,

A handwritten signature in black ink that reads "Pablo Rubinstein". The signature is written in a cursive style with a prominent initial "P" and a horizontal line under the name.

Pablo Rubinstein, M.D.  
Director  
Placental Blood Program,  
New York Blood Center

**1 From**  
 Date 5/8/2001  
 Sender's Name PABLO ROBINSTEIN, MD Phone 212 570-3230  
 Company NY BLOOD CENTER  
 Address 310 East 67th St  
 City NY State NY ZIP 10021

**2 Your Internal Billing Reference**

**3 To**  
 Recipient's Name DOCKETS Mgmt BRANCH Phone  
 Company FOOD AND DRUG ADMINISTRATION  
 Address 5630 FISHERS LANE N.W. 1061  
 City ROCKVILLE State MD ZIP 20852



**4a Express Package Service**

FedEx Priority Overnight  
Next business morning

FedEx Standard Overnight  
Next business afternoon

FedEx 2Day  
Second business day

FedEx Express Saver  
Third business day

NEW FedEx Extra Hours  
Later drop-off with next business afternoon delivery for select locations

**4b Express Freight Service**

FedEx 1Day Freight\*  
Next business day

FedEx 2Day Freight  
Second business day

FedEx 3Day Freight  
Third business day

**5 Packaging**

FedEx Envelope\*

FedEx Pak\*  
Includes FedEx Small Pak, FedEx Large Pak, and FedEx Sturdy Pak

Other Pkg.  
Includes FedEx Box, FedEx Tube, and customer pkg.

**6 Special Handling**

SATURDAY Delivery  
Available only for FedEx Priority Overnight and FedEx 2Day to select ZIP codes

SUNDAY Delivery  
Available only for FedEx Priority Overnight to select ZIP codes

HOLD Weekday at FedEx Location  
Not available with FedEx First Overnight

HOLD Saturday at FedEx Location  
Available only for FedEx Priority Overnight and FedEx 2Day to select locations

Does this shipment contain dangerous goods?  
 No  Yes  
 As per attached Shipper's Declaration

Dry Ice  
Dry Ice, 9, UN 1845 x \_\_\_\_\_ kg

Cargo Aircraft Only

**7 Payment Bill to:**

Enter FedEx Acct. No. or Credit Card No. below.

Sender Acct. No. in Section 1 will be billed.

Recipient  Third Party  Credit Card  Cash/Check

**8 Release Signature** Sign to authorize delivery without obtaining signature.

Total Packages 3 Total Weight \_\_\_\_\_ Total Declared Value\* \$ \_\_\_\_\_

Total Charges 13 Credit Card Auth.

By signing you authorize us to deliver this shipment without obtaining a signature and agree to indemnify and hold us harmless from any resulting claims.  
 Questions? Visit our Web site at [fedex.com](http://fedex.com)  
 or call 1-800-Go-FedEx® (800)463-3333.  
 Rev. Date 12/00 • Part #155815 • ©1994-2000 FedEx • PRINTED IN U.S.A. GBFE 2/01

404